![Antibodies | Free Full-Text | The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From Structure to Prospective Clinical Use Antibodies | Free Full-Text | The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From Structure to Prospective Clinical Use](https://pub.mdpi-res.com/antibodies/antibodies-11-00016/article_deploy/html/images/antibodies-11-00016-g001.png?1645607362)
Antibodies | Free Full-Text | The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From Structure to Prospective Clinical Use
![Bispecific antibodies: BiTE, DARTs, and TandAbs (Part 15- mAbs) | by Roohi Bansal | Biotechnology by TSB | Medium Bispecific antibodies: BiTE, DARTs, and TandAbs (Part 15- mAbs) | by Roohi Bansal | Biotechnology by TSB | Medium](https://miro.medium.com/v2/resize:fit:1400/1*_bn0nrmxeXOXtZCO-W66IQ.png)
Bispecific antibodies: BiTE, DARTs, and TandAbs (Part 15- mAbs) | by Roohi Bansal | Biotechnology by TSB | Medium
![IJMS | Free Full-Text | Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer IJMS | Free Full-Text | Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer](https://www.mdpi.com/ijms/ijms-22-05632/article_deploy/html/images/ijms-22-05632-g001.png)
IJMS | Free Full-Text | Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer
![Frontiers | Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy Frontiers | Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy](https://www.frontiersin.org/files/Articles/379505/fonc-08-00285-HTML/image_m/fonc-08-00285-g001.jpg)
Frontiers | Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy
![Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies | Journal of Hematology & Oncology | Full Text Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs13045-021-01084-4/MediaObjects/13045_2021_1084_Fig1_HTML.png)
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies | Journal of Hematology & Oncology | Full Text
![Bispecific diabody, DART ® , and TandAb fragments [43]. a) Bispecific... | Download Scientific Diagram Bispecific diabody, DART ® , and TandAb fragments [43]. a) Bispecific... | Download Scientific Diagram](https://www.researchgate.net/publication/355874272/figure/fig4/AS:1177400511602688@1657725565037/Bispecific-diabody-DART-R-and-TandAb-fragments-43-a-Bispecific-Diabody-with-two.png)
Bispecific diabody, DART ® , and TandAb fragments [43]. a) Bispecific... | Download Scientific Diagram
![Bispecific antibodies: BiTE, DARTs, and TandAbs (Part 15- mAbs) | by Roohi Bansal | Biotechnology by TSB | Medium Bispecific antibodies: BiTE, DARTs, and TandAbs (Part 15- mAbs) | by Roohi Bansal | Biotechnology by TSB | Medium](https://miro.medium.com/v2/resize:fit:1400/1*eplc-ztYvmMfkWEfoXubPQ.png)
Bispecific antibodies: BiTE, DARTs, and TandAbs (Part 15- mAbs) | by Roohi Bansal | Biotechnology by TSB | Medium
![Life | Free Full-Text | BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML? Life | Free Full-Text | BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?](https://www.mdpi.com/life/life-11-00465/article_deploy/html/images/life-11-00465-g001.png)
Life | Free Full-Text | BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?
![Antibodies | Free Full-Text | Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer Antibodies | Free Full-Text | Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer](https://pub.mdpi-res.com/antibodies/antibodies-05-00006/article_deploy/html/images/antibodies-05-00006-g001.png?1459157346)
Antibodies | Free Full-Text | Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer
![JCI - Dual-Affinity Re-Targeting proteins direct T cell–mediated cytolysis of latently HIV-infected cells JCI - Dual-Affinity Re-Targeting proteins direct T cell–mediated cytolysis of latently HIV-infected cells](https://dm5migu4zj3pb.cloudfront.net/manuscripts/82000/82314/medium/JCI82314.f1.jpg)
JCI - Dual-Affinity Re-Targeting proteins direct T cell–mediated cytolysis of latently HIV-infected cells
![IJMS | Free Full-Text | Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy IJMS | Free Full-Text | Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy](https://www.mdpi.com/ijms/ijms-23-05686/article_deploy/html/images/ijms-23-05686-g003.png)
IJMS | Free Full-Text | Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy
![Schematic overview of the antibody structure and representations of... | Download Scientific Diagram Schematic overview of the antibody structure and representations of... | Download Scientific Diagram](https://www.researchgate.net/publication/344614290/figure/fig1/AS:960142375931942@1605927189827/Schematic-overview-of-the-antibody-structure-and-representations-of-several-dual-TAAs.png)
Schematic overview of the antibody structure and representations of... | Download Scientific Diagram
![Overview of Bispecific Antibody Drug Technology (Part II) – Creative Biolabs Bispecific Antibody Blog Overview of Bispecific Antibody Drug Technology (Part II) – Creative Biolabs Bispecific Antibody Blog](https://www.creative-biolabs.com/blog/bsab/wp-content/uploads/2021/03/640.jpg)